Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Plozasiran (ARO-APOC3) in Adults with Familial Chylomicronemia Syndrome
2021-003680-10Phase 3Active
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Nov 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of plozasiran in primary chylomicronemia (FCS), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Percent change from baseline at Month 10 in fasting triglycerides. Started Nov 2021; status: active.
02
Drugs
plozasiran
03
Conditions
primary chylomicronemia (FCS)
Beyond the preview
Go deeper on 2021-003680-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003680-10.